Quarterly report [Sections 13 or 15(d)]

NON CONTROLLING INTEREST (Details)

v3.26.3
NON CONTROLLING INTEREST (Details) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2026
Jun. 30, 2026
Mar. 31, 2026
Sep. 30, 2025
Jun. 30, 2025
Mar. 31, 2025
Sep. 30, 2026
Sep. 30, 2025
Net loss $ (810,673) $ (1,001,706) $ (1,011,092) $ (811,332) $ (1,377,276) $ (851,764) $ (2,823,471) $ (3,040,372)
Net loss attributable to the non-controlling interest (13,539)     35,759     $ (115,727) $ (118,456)
BioCorRx Pharmaceuticals, Inc [Member]                
Net loss $ (105,363) $ (287,410) $ (269,652) $ 147,763 $ (594,446) $ (42,784)    
Average Non-controlling interest percentage of profit/losses 12.85% 12.85% 24.20% 24.20% 24.20% 24.20%    
Net loss attributable to the non-controlling interest $ (13,539) $ (36,932) $ (65,256) $ 35,759 $ (143,856) $ (10,354)    
Total (115,727)     (118,451)        
Joseph DeSanto MD [Member]                
Net loss $ 0 $ 0 $ 0 $ 0 $ (5) $ (10)    
Average Non-controlling interest percentage of profit/losses 35.00% 35.00% 35.00% 35.00% 35.00% 35.00%    
Net loss attributable to the non-controlling interest $ 0 $ 0 $ 0 $ 0 $ (2) $ (3)    
Total $ 0     $ (5)